= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Porta Siegel

MSACL 2018 EU Abstract

Topic: Tissue Imaging

Podium Presentation in the Ether on Thursday at 9:40 (Chair: Raf Van de Plas)

Bringing Mass Spectrometry to Pathologists for Diagnostics of Frozen Surgically Resected Tissue Specimen

Tiffany Porta Siegel (Presenter)
M4I, Maastricht University

Authors: Tiffany Porta,1,* John F. Cahill,2 Yves J.C. LeBlanc,3 Vilmos Kertesz,2 Gert Eijkel,1 Pierre-Maxence Vaysse,1,4 Heike Grabsch,5 Steven W.M. Olde Damink,4 Gary Van Berkel,2 and Ron Heeren1
(1) Maastricht MultiModal Molecular Imaging institute, Maastricht University, 6229ER Maastricht, The Netherlands; (2) Mass Spectrometry and Laser Spectroscopy Group, Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831-6131, USA; (3) SCIEX , 71 Four Valley Drive, Concord, Ontario L4K 4V8, Canada; (4) Department of Surgery, Maastricht University Medical Centre, 6229ER Maastricht, The Netherlands; (5) Department of Pathology, Maastricht University Medical Centre, 6229ER Maastricht, The Netherlands

Abstract

In current clinical practice, accurate tumor diagnosis during surgery remains challenging. To assess the presence of a malignancy, frozen cut tissue sections are evaluated by the pathologist; but this remains challenging because the morphology of the tissue altered. With our approach, we aim for a rapid, on-line solution by combining an optical microscope directly to a mass spectrometer that could help the pathologist with molecular evaluation / diagnostics of fresh tissue based on molecular profiling within minutes. A predictive statistical model based on PCA-LDA analysis of the patient specimens displayed an accuracy of >90% correct classification rate which allowed to differentiate tumor versus non tumor tissues from patients undergoing surgery for colorectal metastasis. This holds great promises for the diagnostics of frozen section for intraoperative tumor diagnostics.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board MemberyesMSACL Tissue imaging track Sci Committee; MSIS board
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no